Bremelanotide vs PT-141: Which Should You Actually Pick?

Bremelanotide at a glance:

• Drug class: Melanocortin receptor agonist
• Manufacturer: Palatin Technologies / AMAG Pharmaceuticals
• FDA approved: 2019
• Route: subcutaneous injection autoinjector
• Typical frequency: as needed before sexual activity
• Half-life: approximately 2.7 hours
• Cash price (US): $300-$1,000/month

If you're choosing between two specific options, the right framework is rarely "which is better in general" — it's "which is better for me, given my insurance, side-effect tolerance, and dosing preference." We try to make that comparison honest below.

Mechanism

Bremelanotide: Bremelanotide is the FDA-approved name for PT-141. It activates melanocortin receptors in the CNS to improve sexual arousal independently of vascular mechanisms.

PT-141: PT-141 (bremelanotide) is a synthetic analog of α-MSH that activates melanocortin receptors (MC1R, MC3R, MC4R), producing CNS-mediated effects on sexual arousal.

For people new to this comparison, the practical takeaway is that both work through similar pathways but have different pharmacokinetics.

Dosing & Administration

Effectiveness

Bremelanotide: Statistically significant improvement in HSDD desire and distress measures vs placebo.

PT-141: Improvement in sexual desire and reduction in distress in HSDD trials.

In head-to-head comparisons (where they exist), the higher-dose newer agents tend to outperform older ones — sometimes meaningfully. Reference trials: RECONNECT (Kingsberg 2019, Obstet Gynecol) for Bremelanotide; RECONNECT trials (Kingsberg 2019, Obstet Gynecol) — improved desire scores in premenopausal women with HSDD for PT-141.

Side Effects

The two compounds have overlapping side-effect profiles. Common to both:

• nausea
• flushing
• headache
• injection-site reactions
• nausea (very common)
• facial flushing

Important risks worth knowing for both:

• transient blood pressure elevation
• hyperpigmentation
• transient blood pressure increase
• focal hyperpigmentation with frequent use

Cost

Bremelanotide: $300-$1,000/month. PT-141: $300-$1,000/month depending on dose frequency and pharmacy.

Insurance coverage and manufacturer programs change the relative cost picture significantly. See our individual cost guides for Bremelanotide cost and PT-141 cost for the latest numbers.

Which Is Right for You?

The practical decision usually comes down to four factors:

1. What's covered by your insurance? Often the deciding factor
2. What does your prescriber have experience with? Familiarity reduces dosing errors
3. How comfortable are you with injections (or oral dosing if applicable)?
4. What's your tolerance for side effects?

If you and your clinician end up split between Bremelanotide and PT-141, either is a defensible choice in most cases.

Switching Between Them

Switching from Bremelanotide to PT-141 (or the reverse) is usually straightforward but should be done with clinician guidance — particularly to align dose escalation and avoid GI side effects from re-titration.

Bottom Line

Both Bremelanotide and its alternative are defensible choices. The right pick comes from your specific situation — insurance, prescriber, tolerance — not from the molecule alone.

Frequently Asked Questions

Related Reading

• What Is Bremelanotide? Everything You Should Know Before Starting
• Bremelanotide Side Effects: 7 Things to Watch For (and How to Manage Them)
• Bremelanotide Results: What the Real Numbers Show in 2026
• Why Bremelanotide Costs So Much (and 5 Ways to Pay Less)
• hCG: The Complete 2026 Guide (Mechanism, Dosing, Cost)
• What Is Oxytocin? Everything You Should Know Before Starting

Sources

• Skorupskaite K et al. Kisspeptin and Reproduction in Humans. Hum Reprod Update 2014;20:485.
• Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. Obstet Gynecol 2019;134:899.

This page is informational only and is not a personalized recommendation. The right choice depends on your individual situation.